ID   ACK1_HUMAN              Reviewed;        1038 AA.
AC   Q07912; Q6ZMQ0; Q8N6U7; Q96H59;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   10-MAY-2017, entry version 182.
DE   RecName: Full=Activated CDC42 kinase 1;
DE            Short=ACK-1;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:20333297};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068};
DE   AltName: Full=Tyrosine kinase non-receptor protein 2;
GN   Name=TNK2; Synonyms=ACK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDC42.
RC   TISSUE=Hippocampus;
RX   PubMed=8497321; DOI=10.1038/363364a0;
RA   Manser E., Leung T., Salihuddin H., Tan L., Lim L.;
RT   "A non-receptor tyrosine kinase that inhibits the GTPase activity of
RT   p21cdc42.";
RL   Nature 363:364-367(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT
RP   LEU-725.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH CSPG4.
RX   PubMed=10587647; DOI=10.1038/70302;
RA   Eisenmann K.M., McCarthy J.B., Simpson M.A., Keely P.J., Guan J.-L.,
RA   Tachibana K., Lim L., Manser E., Furcht L.T., Iida J.;
RT   "Melanoma chondroitin sulphate proteoglycan regulates cell spreading
RT   through Cdc42, Ack-1 and p130cas.";
RL   Nat. Cell Biol. 1:507-513(1999).
RN   [6]
RP   FUNCTION AS MCF2 KINASE, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=10652228; DOI=10.1006/bbrc.2000.2106;
RA   Kato J., Kaziro Y., Satoh T.;
RT   "Activation of the guanine nucleotide exchange factor Dbl following
RT   ACK1-dependent tyrosine phosphorylation.";
RL   Biochem. Biophys. Res. Commun. 268:141-147(2000).
RN   [7]
RP   FUNCTION.
RX   PubMed=11278436; DOI=10.1074/jbc.M008795200;
RA   Teo M., Tan L., Lim L., Manser E.;
RT   "The tyrosine kinase ACK1 associates with clathrin-coated vesicles
RT   through a binding motif shared by arrestin and other adaptors.";
RL   J. Biol. Chem. 276:18392-18398(2001).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14733946; DOI=10.1016/j.bbrc.2003.12.137;
RA   Ahmed I., Calle Y., Sayed M.A., Kamal J.M., Rengaswamy P., Manser E.,
RA   Meiners S., Nur-E-Kamal A.;
RT   "Cdc42-dependent nuclear translocation of non-receptor tyrosine
RT   kinase, ACK.";
RL   Biochem. Biophys. Res. Commun. 314:571-579(2004).
RN   [9]
RP   AUTOPHOSPHORYLATION, INTERACTION WITH HSP90AB1; MTERK AND WWOX, AND
RP   MUTAGENESIS OF LYS-158 AND LEU-487.
RX   PubMed=16288044; DOI=10.1158/0008-5472.CAN-05-1127;
RA   Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.;
RT   "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role
RT   of Ack1 in polyubiquitination of tumor suppressor Wwox.";
RL   Cancer Res. 65:10514-10523(2005).
RN   [10]
RP   INTERACTION WITH SNX9, AND SUBCELLULAR LOCATION.
RX   PubMed=16137687; DOI=10.1016/j.febslet.2005.07.093;
RA   Yeow-Fong L., Lim L., Manser E.;
RT   "SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector
RT   ACK1.";
RL   FEBS Lett. 579:5040-5048(2005).
RN   [11]
RP   FUNCTION AS WAS KINASE, INTERACTION WITH WASL, CATALYTIC ACTIVITY, AND
RP   COFACTOR.
RX   PubMed=16257963; DOI=10.1074/jbc.M506996200;
RA   Yokoyama N., Lougheed J., Miller W.T.;
RT   "Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual
RT   hydroxyamino acid specificity in a tyrosine kinase.";
RL   J. Biol. Chem. 280:42219-42226(2005).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [13]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16247015; DOI=10.1073/pnas.0508014102;
RA   van der Horst E.H., Degenhardt Y.Y., Strelow A., Slavin A., Chinn L.,
RA   Orf J., Rong M., Li S., See L.-H., Nguyen K.Q.C., Hoey T., Wesche H.,
RA   Powers S.;
RT   "Metastatic properties and genomic amplification of the tyrosine
RT   kinase gene ACK1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15901-15906(2005).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   FUNCTION IN CELL MIGRATION, AND INTERACTION WITH BCAR1; CDC42 AND CRK.
RX   PubMed=17038317; DOI=10.1074/jbc.M604342200;
RA   Modzelewska K., Newman L.P., Desai R., Keely P.J.;
RT   "Ack1 mediates Cdc42-dependent cell migration and signaling to
RT   p130Cas.";
RL   J. Biol. Chem. 281:37527-37535(2006).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT TYR-284.
RX   PubMed=16472662; DOI=10.1016/S0076-6879(06)06018-6;
RA   Yokoyama N., Miller W.T.;
RT   "Purification and enzyme activity of ACK1.";
RL   Methods Enzymol. 406:250-260(2006).
RN   [17]
RP   INTERACTION WITH AR.
RX   PubMed=17494760; DOI=10.1073/pnas.0700420104;
RA   Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E.,
RA   Mohler J.L., Earp H.S., Whang Y.E.;
RT   "Activated Cdc42-associated kinase Ack1 promotes prostate cancer
RT   progression via androgen receptor tyrosine phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8438-8443(2007).
RN   [18]
RP   INTERACTION WITH NPHP1.
RX   PubMed=18477472; DOI=10.1016/j.bbrc.2008.05.016;
RA   Eley L., Moochhala S.H., Simms R., Hildebrandt F., Sayer J.A.;
RT   "Nephrocystin-1 interacts directly with Ack1 and is expressed in human
RT   collecting duct.";
RL   Biochem. Biophys. Res. Commun. 371:877-882(2008).
RN   [19]
RP   FUNCTION.
RX   PubMed=18435854; DOI=10.1186/bcr2087;
RA   Howlin J., Rosenkvist J., Andersson T.;
RT   "TNK2 preserves epidermal growth factor receptor expression on the
RT   cell surface and enhances migration and invasion of human breast
RT   cancer cells.";
RL   Breast Cancer Res. 10:R36-R36(2008).
RN   [20]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18262180; DOI=10.1016/j.yexcr.2007.12.017;
RA   Groevdal L.M., Johannessen L.E., Roedland M.S., Madshus I.H.,
RA   Stang E.;
RT   "Dysregulation of Ack1 inhibits down-regulation of the EGF receptor.";
RL   Exp. Cell Res. 314:1292-1300(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-881, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   INTERACTION WITH NEDD4, AND UBIQUITINATION.
RX   PubMed=19144635; DOI=10.1074/jbc.M806877200;
RA   Chan W., Tian R., Lee Y.-F., Sit S.T., Lim L., Manser E.;
RT   "Down-regulation of active ACK1 is mediated by association with the E3
RT   ubiquitin ligase Nedd4-2.";
RL   J. Biol. Chem. 284:8185-8194(2009).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH AXL; LTK; PDGFRL AND GRB2.
RX   PubMed=19815557; DOI=10.1074/jbc.M109.072660;
RA   Pao-Chun L., Chan P.M., Chan W., Manser E.;
RT   "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases
RT   is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.";
RL   J. Biol. Chem. 284:34954-34963(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-284 AND SER-724, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-284, AND DOMAIN
RP   SAM-LIKE.
RX   PubMed=20979614; DOI=10.1186/1471-2091-11-42;
RA   Prieto-Echaguee V., Gucwa A., Brown D.A., Miller W.T.;
RT   "Regulation of Ack1 localization and activity by the amino-terminal
RT   SAM domain.";
RL   BMC Biochem. 11:42-42(2010).
RN   [27]
RP   FUNCTION AS AR KINASE, AND ENZYME REGULATION.
RX   PubMed=20383201; DOI=10.1038/onc.2010.103;
RA   Liu Y., Karaca M., Zhang Z., Gioeli D., Earp H.S., Whang Y.E.;
RT   "Dasatinib inhibits site-specific tyrosine phosphorylation of androgen
RT   receptor by Ack1 and Src kinases.";
RL   Oncogene 29:3208-3216(2010).
RN   [28]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH AKT1,
RP   SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT LYS-346,
RP   PHOSPHORYLATION AT TYR-284, AND TISSUE SPECIFICITY.
RX   PubMed=20333297; DOI=10.1371/journal.pone.0009646;
RA   Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W.,
RA   Lopez A.S., Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S.,
RA   Cheng J.Q., Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.;
RT   "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its
RT   activation.";
RL   PLoS ONE 5:E9646-E9646(2010).
RN   [29]
RP   PHOSPHORYLATION AT TYR-284, TISSUE SPECIFICITY, AND ENZYME REGULATION.
RX   PubMed=20623637; DOI=10.1002/pros.21163;
RA   Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H.,
RA   Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P.;
RT   "Effect of Ack1 tyrosine kinase inhibitor on ligand-independent
RT   androgen receptor activity.";
RL   Prostate 70:1274-1285(2010).
RN   [30]
RP   PHOSPHORYLATION AT TYR-284, AND INTERACTION WITH SRC.
RX   PubMed=21309750; DOI=10.1042/BJ20102156;
RA   Chan W., Sit S.T., Manser E.;
RT   "The Cdc42-associated kinase ACK1 is not auto-inhibited but requires
RT   Src for activation.";
RL   Biochem. J. 435:355-364(2011).
RN   [31]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-284; TYR-518;
RP   TYR-827; TYR-859 AND TYR-872.
RX   PubMed=21169560; DOI=10.1091/mbc.E10-07-0637;
RA   Shen H., Ferguson S.M., Dephoure N., Park R., Yang Y.,
RA   Volpicelli-Daley L., Gygi S., Schlessinger J., De Camilli P.;
RT   "Constitutive activated Cdc42-associated kinase (Ack) phosphorylation
RT   at arrested endocytic clathrin-coated pits of cells that lack
RT   dynamin.";
RL   Mol. Biol. Cell 22:493-502(2011).
RN   [32]
RP   REVIEW ON TUMOR GROWTH.
RX   PubMed=20432460; DOI=10.1002/jcp.22162;
RA   Mahajan K., Mahajan N.P.;
RT   "Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.";
RL   J. Cell. Physiol. 224:327-333(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   STRUCTURE BY NMR OF 448-489.
RX   PubMed=10360579; DOI=10.1038/20732;
RA   Mott H.R., Owen D., Nietlispach D., Lowe P.N., Manser E., Lim L.,
RA   Laue E.D.;
RT   "Structure of the small G protein Cdc42 bound to the GTPase-binding
RT   domain of ACK.";
RL   Nature 399:384-388(1999).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 107-395, AND PHOSPHORYLATION
RP   AT TYR-284.
RX   PubMed=15308621; DOI=10.1074/jbc.M406703200;
RA   Lougheed J.C., Chen R.-H., Mak P., Stout T.J.;
RT   "Crystal structures of the phosphorylated and unphosphorylated kinase
RT   domains of the Cdc42-associated tyrosine kinase ACK1.";
RL   J. Biol. Chem. 279:44039-44045(2004).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 117-392 IN COMPLEX WITH
RP   INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=18993068; DOI=10.1016/j.bmcl.2008.10.092;
RA   Kopecky D.J., Hao X., Chen Y., Fu J., Jiao X., Jaen J.C.,
RA   Cardozo M.G., Liu J., Wang Z., Walker N.P., Wesche H., Li S.,
RA   Farrelly E., Xiao S.H., Kayser F.;
RT   "Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-
RT   d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 18:6352-6356(2008).
RN   [37]
RP   VARIANTS LEU-34; ARG-71; GLN-99; TRP-99; MET-152; LYS-346; ILE-409;
RP   SER-507; LEU-725; GLN-748 AND HIS-1038.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [38]
RP   VARIANT MET-638, INTERACTION WITH NEDD4 AND NEDD4L, AND
RP   CHARACTERIZATION OF VARIANT MET-638.
RX   PubMed=23686771; DOI=10.1002/ana.23934;
RA   Hitomi Y., Heinzen E.L., Donatello S., Dahl H.H., Damiano J.A.,
RA   McMahon J.M., Berkovic S.F., Scheffer I.E., Legros B., Rai M.,
RA   Weckhuysen S., Suls A., De Jonghe P., Pandolfo M., Goldstein D.B.,
RA   Van Bogaert P., Depondt C.;
RT   "Mutations in TNK2 in severe autosomal recessive infantile onset
RT   epilepsy.";
RL   Ann. Neurol. 74:496-501(2013).
CC   -!- FUNCTION: Non-receptor tyrosine-protein and serine/threonine-
CC       protein kinase that is implicated in cell spreading and migration,
CC       cell survival, cell growth and proliferation. Transduces
CC       extracellular signals to cytosolic and nuclear effectors.
CC       Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in
CC       trafficking and clathrin-mediated endocytosis through binding to
CC       epidermal growth factor receptor (EGFR) and clathrin. Binds to
CC       both poly- and mono-ubiquitin and regulates ligand-induced
CC       degradation of EGFR, thereby contributing to the accumulation of
CC       EGFR at the limiting membrane of early endosomes. Downstream
CC       effector of CDC42 which mediates CDC42-dependent cell migration
CC       via phosphorylation of BCAR1. May be involved both in adult
CC       synaptic function and plasticity and in brain development.
CC       Activates AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates
CC       AR on 'Tyr-267' and 'Tyr-363' thereby promoting its recruitment to
CC       androgen-responsive enhancers (AREs). Phosphorylates WWOX on 'Tyr-
CC       287'. Phosphorylates MCF2, thereby enhancing its activity as a
CC       guanine nucleotide exchange factor (GEF) toward Rho family
CC       proteins. Contributes to the control of AXL receptor levels.
CC       Confers metastatic properties on cancer cells and promotes tumor
CC       growth by negatively regulating tumor suppressor such as WWOX and
CC       positively regulating pro-survival factors such as AKT1 and AR.
CC       {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:11278436,
CC       ECO:0000269|PubMed:16247015, ECO:0000269|PubMed:16257963,
CC       ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:17038317,
CC       ECO:0000269|PubMed:18262180, ECO:0000269|PubMed:18435854,
CC       ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20333297,
CC       ECO:0000269|PubMed:20383201}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:10652228,
CC       ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:16472662,
CC       ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:20333297}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10652228,
CC         ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:20333297};
CC   -!- ENZYME REGULATION: Inhibited by AIM-100 (4-amino-5,6-biaryl-
CC       furo[2,3-d]pyrimidine), which suppresses activating
CC       phosphorylation at Tyr-284. Repressed by dasatinib.
CC       {ECO:0000269|PubMed:20383201, ECO:0000269|PubMed:20623637}.
CC   -!- SUBUNIT: Interacts with NEDD4 (via WW3 domain). NEDD4L and EGF
CC       promote association with NEDD4 (By similarity). Homodimer.
CC       Interacts with AR, CDC42, WWASL and WWOX. Interacts with CSPG4
CC       (activated). Interacts with MERTK (activated); stimulates
CC       autophosphorylation. May interact (phosphorylated) with HSP90AB1;
CC       maintains kinase activity. Interacts with NPHP1. Interacts with
CC       SNX9 (via SH3 domain). Interacts with SRC (via SH2 and SH3
CC       domain). Interacts with EGFR, and this interaction is dependent on
CC       EGF stimulation and kinase activity of EGFR. Interacts (via kinase
CC       domain) with AKT1. Part of a collagen stimulated complex involved
CC       in cell migration composed of CDC42, CRK, TNK2 and BCAR1/p130cas.
CC       Interacts with BCAR1/p130cas via SH3 domains. Forms complexes with
CC       GRB2 and numerous receptor tyrosine kinases (RTK) including LTK,
CC       AXL or PDGFRL, in which GRB2 promotes RTK recruitment by TNK2.
CC       {ECO:0000250, ECO:0000269|PubMed:10587647,
CC       ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:16257963,
CC       ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:17038317,
CC       ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:18477472,
CC       ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:19144635,
CC       ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20333297,
CC       ECO:0000269|PubMed:20979614, ECO:0000269|PubMed:21309750,
CC       ECO:0000269|PubMed:23686771, ECO:0000269|PubMed:8497321}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-603457, EBI-603457;
CC       P29972:AQP1; NbExp=3; IntAct=EBI-603457, EBI-745213;
CC       P56945:BCAR1; NbExp=5; IntAct=EBI-603457, EBI-702093;
CC       P60953-2:CDC42; NbExp=2; IntAct=EBI-603457, EBI-287394;
CC       Q00610:CLTC; NbExp=2; IntAct=EBI-603457, EBI-354967;
CC       P07902:GALT; NbExp=3; IntAct=EBI-11994780, EBI-750827;
CC       Q9HC98:NEK6; NbExp=3; IntAct=EBI-603457, EBI-740364;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-603457, EBI-945833;
CC       O60880:SH2D1A; NbExp=3; IntAct=EBI-11994780, EBI-6983382;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Nucleus. Endosome. Cell
CC       junction, adherens junction {ECO:0000250}. Cytoplasmic vesicle
CC       membrane; Peripheral membrane protein; Cytoplasmic side.
CC       Cytoplasmic vesicle, clathrin-coated vesicle. Membrane, clathrin-
CC       coated pit. Note=The Tyr-284 phosphorylated form is found both in
CC       the membrane and nucleus. Colocalizes with EGFR on endosomes.
CC       Nuclear translocation is CDC42-dependent.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q07912-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q07912-2; Sequence=VSP_008655, VSP_008656;
CC         Note=No experimental confirmation available. May be produced at
CC         very low levels due to a premature stop codon in the mRNA,
CC         leading to nonsense-mediated mRNA decay.;
CC       Name=3;
CC         IsoId=Q07912-3; Sequence=VSP_037284, VSP_037285, VSP_037286;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: The Tyr-284 phosphorylated form shows a
CC       significant increase in expression in breast cancers during the
CC       progressive stages i.e. normal to hyperplasia (ADH), ductal
CC       carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and
CC       lymph node metastatic (LNMM) stages. It also shows a significant
CC       increase in expression in prostate cancers during the progressive
CC       stages. {ECO:0000269|PubMed:16247015, ECO:0000269|PubMed:20333297,
CC       ECO:0000269|PubMed:20623637}.
CC   -!- DOMAIN: The EBD (EGFR-binding domain) domain is necessary for
CC       interaction with EGFR. {ECO:0000250}.
CC   -!- DOMAIN: The SAM-like domain is necessary for NEDD4-mediated
CC       ubiquitination. Promotes membrane localization and dimerization to
CC       allow for autophosphorylation. {ECO:0000269|PubMed:20979614}.
CC   -!- DOMAIN: The UBA domain binds both poly- and mono-ubiquitin.
CC       {ECO:0000269|PubMed:20979614}.
CC   -!- PTM: Autophosphorylation regulates kinase activity.
CC       Phosphorylation on Tyr-518 is required for interaction with SRC
CC       and is observed during association with clathrin-coated pits.
CC       {ECO:0000269|PubMed:15308621, ECO:0000269|PubMed:16472662,
CC       ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20623637,
CC       ECO:0000269|PubMed:20979614, ECO:0000269|PubMed:21169560,
CC       ECO:0000269|PubMed:21309750}.
CC   -!- PTM: Polyubiquitinated by NEDD4 and NEDD4L. Degradation can be
CC       induced by EGF and is lysosome-dependent (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH08884.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L13738; AAA53570.2; -; mRNA.
DR   EMBL; AK131539; BAD18675.1; -; mRNA.
DR   EMBL; AC124944; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008884; AAH08884.1; ALT_SEQ; mRNA.
DR   EMBL; BC028164; AAH28164.1; -; mRNA.
DR   CCDS; CCDS33927.1; -. [Q07912-3]
DR   CCDS; CCDS33928.1; -. [Q07912-1]
DR   PIR; S33596; S33596.
DR   RefSeq; NP_001010938.1; NM_001010938.1. [Q07912-3]
DR   RefSeq; NP_001294975.1; NM_001308046.1.
DR   RefSeq; NP_005772.3; NM_005781.4. [Q07912-1]
DR   UniGene; Hs.518513; -.
DR   PDB; 1CF4; NMR; -; B=448-489.
DR   PDB; 1U46; X-ray; 2.00 A; A/B=109-395.
DR   PDB; 1U4D; X-ray; 2.10 A; A/B=109-395.
DR   PDB; 1U54; X-ray; 2.80 A; A/B=109-395.
DR   PDB; 3EQP; X-ray; 2.30 A; A/B=117-392.
DR   PDB; 3EQR; X-ray; 2.00 A; A/B=117-392.
DR   PDB; 4EWH; X-ray; 2.50 A; A/B=117-391.
DR   PDB; 4HZR; X-ray; 1.31 A; A/B=115-389.
DR   PDB; 4HZS; X-ray; 3.23 A; A/B/C/D=115-453.
DR   PDB; 4ID7; X-ray; 3.00 A; A=117-389.
DR   PDBsum; 1CF4; -.
DR   PDBsum; 1U46; -.
DR   PDBsum; 1U4D; -.
DR   PDBsum; 1U54; -.
DR   PDBsum; 3EQP; -.
DR   PDBsum; 3EQR; -.
DR   PDBsum; 4EWH; -.
DR   PDBsum; 4HZR; -.
DR   PDBsum; 4HZS; -.
DR   PDBsum; 4ID7; -.
DR   ProteinModelPortal; Q07912; -.
DR   SMR; Q07912; -.
DR   BioGrid; 115485; 77.
DR   DIP; DIP-33858N; -.
DR   IntAct; Q07912; 34.
DR   MINT; MINT-1382124; -.
DR   STRING; 9606.ENSP00000371341; -.
DR   BindingDB; Q07912; -.
DR   ChEMBL; CHEMBL4599; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB04367; Debromohymenialdisine.
DR   GuidetoPHARMACOLOGY; 2246; -.
DR   iPTMnet; Q07912; -.
DR   PhosphoSitePlus; Q07912; -.
DR   BioMuta; TNK2; -.
DR   DMDM; 229462980; -.
DR   EPD; Q07912; -.
DR   MaxQB; Q07912; -.
DR   PaxDb; Q07912; -.
DR   PeptideAtlas; Q07912; -.
DR   PRIDE; Q07912; -.
DR   DNASU; 10188; -.
DR   Ensembl; ENST00000333602; ENSP00000329425; ENSG00000061938. [Q07912-1]
DR   Ensembl; ENST00000381916; ENSP00000371341; ENSG00000061938. [Q07912-3]
DR   Ensembl; ENST00000439230; ENSP00000395588; ENSG00000061938. [Q07912-2]
DR   GeneID; 10188; -.
DR   KEGG; hsa:10188; -.
DR   UCSC; uc003fvt.2; human. [Q07912-1]
DR   CTD; 10188; -.
DR   DisGeNET; 10188; -.
DR   GeneCards; TNK2; -.
DR   H-InvDB; HIX0003961; -.
DR   HGNC; HGNC:19297; TNK2.
DR   HPA; HPA041954; -.
DR   MalaCards; TNK2; -.
DR   MIM; 606994; gene.
DR   neXtProt; NX_Q07912; -.
DR   OpenTargets; ENSG00000061938; -.
DR   Orphanet; 391316; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression.
DR   PharmGKB; PA134909759; -.
DR   eggNOG; KOG0199; Eukaryota.
DR   eggNOG; ENOG410XPRC; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000168225; -.
DR   HOVERGEN; HBG100429; -.
DR   InParanoid; Q07912; -.
DR   KO; K08886; -.
DR   OMA; KTMPTTQ; -.
DR   OrthoDB; EOG091G03HT; -.
DR   PhylomeDB; Q07912; -.
DR   TreeFam; TF316643; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   SignaLink; Q07912; -.
DR   SIGNOR; Q07912; -.
DR   ChiTaRS; TNK2; human.
DR   EvolutionaryTrace; Q07912; -.
DR   GeneWiki; TNK2; -.
DR   GenomeRNAi; 10188; -.
DR   PRO; PR:Q07912; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000061938; -.
DR   CleanEx; HS_TNK2; -.
DR   ExpressionAtlas; Q07912; baseline and differential.
DR   Genevisible; Q07912; HS.
DR   GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0070436; C:Grb2-EGFR complex; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0005095; F:GTPase inhibitor activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0050699; F:WW domain binding; ISS:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:2000369; P:regulation of clathrin-dependent endocytosis; IDA:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 4.10.680.10; -; 1.
DR   InterPro; IPR015116; Cdc42_binding_dom-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR021619; Mig-6.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF09027; GTPase_binding; 1.
DR   Pfam; PF11555; Inhibitor_Mig-6; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF14604; SH3_9; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Coated pit; Complete proteome; Cytoplasmic vesicle;
KW   Endocytosis; Endosome; Kinase; Magnesium; Membrane; Metal-binding;
KW   Methylation; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   SH3 domain; Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN         1   1038       Activated CDC42 kinase 1.
FT                                /FTId=PRO_0000088058.
FT   DOMAIN      126    385       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      386    448       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      454    466       CRIB.
FT   DOMAIN      958    996       UBA.
FT   NP_BIND     132    140       ATP.
FT   REGION        1    110       SAM-like domain.
FT   REGION      623    652       Required for interaction with SRC.
FT                                {ECO:0000269|PubMed:21309750}.
FT   REGION      632    635       Required for interaction with NEDD4.
FT                                {ECO:0000250}.
FT   REGION      733    876       EBD domain. {ECO:0000250}.
FT   COMPBIAS    577    958       Pro-rich.
FT   ACT_SITE    252    252       Proton acceptor.
FT   BINDING     158    158       ATP.
FT   MOD_RES     284    284       Phosphotyrosine; by SRC and
FT                                autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:15308621,
FT                                ECO:0000269|PubMed:16472662,
FT                                ECO:0000269|PubMed:20333297,
FT                                ECO:0000269|PubMed:20623637,
FT                                ECO:0000269|PubMed:20979614,
FT                                ECO:0000269|PubMed:21169560,
FT                                ECO:0000269|PubMed:21309750}.
FT   MOD_RES     518    518       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21169560}.
FT   MOD_RES     724    724       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     827    827       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21169560}.
FT   MOD_RES     839    839       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:O54967}.
FT   MOD_RES     859    859       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21169560}.
FT   MOD_RES     872    872       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21169560}.
FT   MOD_RES     881    881       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   VAR_SEQ       1      1       M -> MLEARPPRTQGSDAAGAAAGRGLRALLLSLTAAAGI
FT                                WGSMGERSAYQRLAGGEEGPQRLGGGRM (in isoform
FT                                3). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_037284.
FT   VAR_SEQ     485    528       LYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQ
FT                                DPL -> CPFSAFSPGHPPAETCGQVLWTGRREACASDPRL
FT                                HPVSSRTKGL (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_008655.
FT   VAR_SEQ     514    514       K -> KREPPPRPPQPAFFTQ (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_037285.
FT   VAR_SEQ     529   1038       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_008656.
FT   VAR_SEQ     965    994       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_037286.
FT   VARIANT      34     34       R -> L (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032792.
FT   VARIANT      71     71       K -> R (in dbSNP:rs56036945).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032793.
FT   VARIANT      99     99       R -> Q (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation; undergoes
FT                                autoactivation and causes phosphorylation
FT                                on Tyr-284 leading to activation of AKT1;
FT                                dbSNP:rs113498671).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032794.
FT   VARIANT      99     99       R -> W (in dbSNP:rs3747673).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032795.
FT   VARIANT     152    152       T -> M (in dbSNP:rs56161912).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032796.
FT   VARIANT     346    346       E -> K (in an ovarian endometrioid cancer
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:20333297}.
FT                                /FTId=VAR_032797.
FT   VARIANT     409    409       M -> I (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032798.
FT   VARIANT     507    507       P -> S (in dbSNP:rs35759128).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032799.
FT   VARIANT     638    638       V -> M (found in patients with childhood-
FT                                onset epilepsy; unknown pathological
FT                                significance; loss of interaction with
FT                                NEDD4 and NEDD4L; increased protein
FT                                abundance; dbSNP:rs201407161).
FT                                {ECO:0000269|PubMed:23686771}.
FT                                /FTId=VAR_076966.
FT   VARIANT     725    725       P -> L (in dbSNP:rs56260729).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032800.
FT   VARIANT     748    748       R -> Q (in dbSNP:rs57872314).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032801.
FT   VARIANT     802    802       P -> L (in dbSNP:rs3749333).
FT                                /FTId=VAR_057115.
FT   VARIANT    1038   1038       R -> H (in dbSNP:rs13433937).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032802.
FT   MUTAGEN     158    158       K->R: Loss of autophosphorylation.
FT                                {ECO:0000269|PubMed:16288044}.
FT   MUTAGEN     487    487       L->F: Constantly active kinase.
FT                                {ECO:0000269|PubMed:16288044}.
FT   CONFLICT    138    138       G -> V (in Ref. 4; AAH08884).
FT                                {ECO:0000305}.
FT   CONFLICT    304    352       TRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKID
FT                                KEGERLPR -> PPWRDISASSSTQFPHAVPCFPTSLLAKL
FT                                LLRHSVPASSREIKLVSILC (in Ref. 4;
FT                                AAH08884). {ECO:0000305}.
FT   CONFLICT    353   1038       Missing (in Ref. 4; AAH08884).
FT                                {ECO:0000305}.
FT   CONFLICT    586    586       A -> P (in Ref. 1; AAA53570).
FT                                {ECO:0000305}.
FT   CONFLICT    722    722       Missing (in Ref. 1; AAA53570).
FT                                {ECO:0000305}.
FT   CONFLICT    838    840       PRA -> AG (in Ref. 1; AAA53570).
FT                                {ECO:0000305}.
FT   STRAND      118    120       {ECO:0000244|PDB:4HZS}.
FT   HELIX       123    125       {ECO:0000244|PDB:4HZR}.
FT   STRAND      126    133       {ECO:0000244|PDB:4HZR}.
FT   STRAND      140    146       {ECO:0000244|PDB:4HZR}.
FT   STRAND      148    150       {ECO:0000244|PDB:3EQP}.
FT   STRAND      152    159       {ECO:0000244|PDB:4HZR}.
FT   TURN        164    166       {ECO:0000244|PDB:3EQR}.
FT   HELIX       171    181       {ECO:0000244|PDB:4HZR}.
FT   STRAND      192    196       {ECO:0000244|PDB:4HZR}.
FT   STRAND      198    200       {ECO:0000244|PDB:4HZR}.
FT   STRAND      202    206       {ECO:0000244|PDB:4HZR}.
FT   HELIX       213    219       {ECO:0000244|PDB:4HZR}.
FT   HELIX       221    223       {ECO:0000244|PDB:4HZR}.
FT   HELIX       226    245       {ECO:0000244|PDB:4HZR}.
FT   HELIX       255    257       {ECO:0000244|PDB:4HZR}.
FT   STRAND      258    262       {ECO:0000244|PDB:4HZR}.
FT   STRAND      265    268       {ECO:0000244|PDB:4HZR}.
FT   HELIX       273    276       {ECO:0000244|PDB:4HZS}.
FT   STRAND      283    285       {ECO:0000244|PDB:1U46}.
FT   HELIX       288    290       {ECO:0000244|PDB:3EQP}.
FT   HELIX       294    296       {ECO:0000244|PDB:4HZR}.
FT   HELIX       299    304       {ECO:0000244|PDB:4HZR}.
FT   STRAND      306    308       {ECO:0000244|PDB:1U46}.
FT   HELIX       309    324       {ECO:0000244|PDB:4HZR}.
FT   TURN        325    327       {ECO:0000244|PDB:4HZS}.
FT   TURN        330    333       {ECO:0000244|PDB:4HZR}.
FT   HELIX       336    344       {ECO:0000244|PDB:4HZR}.
FT   HELIX       358    367       {ECO:0000244|PDB:4HZR}.
FT   HELIX       372    374       {ECO:0000244|PDB:4HZR}.
FT   HELIX       378    387       {ECO:0000244|PDB:4HZR}.
FT   STRAND      392    394       {ECO:0000244|PDB:4HZS}.
FT   STRAND      402    404       {ECO:0000244|PDB:4HZS}.
FT   STRAND      412    417       {ECO:0000244|PDB:4HZS}.
FT   STRAND      419    421       {ECO:0000244|PDB:4HZS}.
FT   STRAND      423    432       {ECO:0000244|PDB:4HZS}.
FT   STRAND      435    439       {ECO:0000244|PDB:4HZS}.
FT   HELIX       440    443       {ECO:0000244|PDB:4HZS}.
FT   STRAND      449    451       {ECO:0000244|PDB:1CF4}.
FT   TURN        484    486       {ECO:0000244|PDB:1CF4}.
SQ   SEQUENCE   1038 AA;  114569 MW;  74A1980665BC3E6B CRC64;
     MQPEEGTGWL LELLSEVQLQ QYFLRLRDDL NVTRLSHFEY VKNEDLEKIG MGRPGQRRLW
     EAVKRRKALC KRKSWMSKVF SGKRLEAEFP PHHSQSTFRK TSPAPGGPAG EGPLQSLTCL
     IGEKDLRLLE KLGDGSFGVV RRGEWDAPSG KTVSVAVKCL KPDVLSQPEA MDDFIREVNA
     MHSLDHRNLI RLYGVVLTPP MKMVTELAPL GSLLDRLRKH QGHFLLGTLS RYAVQVAEGM
     GYLESKRFIH RDLAARNLLL ATRDLVKIGD FGLMRALPQN DDHYVMQEHR KVPFAWCAPE
     SLKTRTFSHA SDTWMFGVTL WEMFTYGQEP WIGLNGSQIL HKIDKEGERL PRPEDCPQDI
     YNVMVQCWAH KPEDRPTFVA LRDFLLEAQP TDMRALQDFE EPDKLHIQMN DVITVIEGRA
     ENYWWRGQNT RTLCVGPFPR NVVTSVAGLS AQDISQPLQN SFIHTGHGDS DPRHCWGFPD
     RIDELYLGNP MDPPDLLSVE LSTSRPPQHL GGVKKPTYDP VSEDQDPLSS DFKRLGLRKP
     GLPRGLWLAK PSARVPGTKA SRGSGAEVTL IDFGEEPVVP ALRPCAPSLA QLAMDACSLL
     DETPPQSPTR ALPRPLHPTP VVDWDARPLP PPPAYDDVAQ DEDDFEICSI NSTLVGAGVP
     AGPSQGQTNY AFVPEQARPP PPLEDNLFLP PQGGGKPPSS AQTAEIFQAL QQECMRQLQA
     PAGSPAPSPS PGGDDKPQVP PRVPIPPRPT RPHVQLSPAP PGEEETSQWP GPASPPRVPP
     REPLSPQGSR TPSPLVPPGS SPLPPRLSSS PGKTMPTTQS FASDPKYATP QVIQAPGPRA
     GPCILPIVRD GKKVSSTHYY LLPERPSYLE RYQRFLREAQ SPEEPTPLPV PLLLPPPSTP
     APAAPTATVR PMPQAALDPK ANFSTNNSNP GARPPPPRAT ARLPQRGCPG DGPEAGRPAD
     KIQMAMVHGV TTEECQAALQ CHGWSVQRAA QYLKVEQLFG LGLRPRGECH KVLEMFDWNL
     EQAGCHLLGS WGPAHHKR
//
